NRx Pharmaceuticals (Nasdaq: NRXP) to Present Keynote Address on Ketamine Efficacy and Risks at Upcoming Sachs Neuroscience Innovation Forum in San Francisco

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (“NRx Pharmaceuticals”, (NRx), a clinical-stage biopharmaceutical company today announced that it has been selected to give the keynote address entitled “Ketamine for Suicidal Depression: The Benefits are Clear, But So are the Risks,” at the upcoming Sachs Neuroscience Innovation Forum in San Francisco, CA on January 7, 2024. The Company plans to file a New Drug Application for Ketamine in 2024, both in the United States and the European Union in partnership with the Fondation FundaMental of Paris, FR.

“When FDA first granted us Fast Track Designation to develop ketamine as a life-saving drug for the treatment of suicidal depression in 2017, evidence of efficacy was shown in only small clinical trials,” said Jonathan Javitt, MD, MPH, Founder, Chairman, and Chief Scientist of NRx Pharmaceuticals. “Ketamine’s efficacy was so dramatic that ketamine became a standard of care ahead of the large clinical trials required for drug approval. Ketamine, as expected, now been demonstrated to be dramatically superior to placebo in large clinical trials. What could not be predicted is that ketamine has been shown to be at least as good as (i.e. non-inferior) to electroshock therapy (ECT), and in one trial demonstrated superiority over ECT. The problem is that ketamine is sold only in a 70 year old formulation designed for use in human and veterinary anesthesia and cannot be used in the clinic setting without quasi-legal compounding in a local pharmacy, a practice that FDA has warned against. We have partnered with Nephron Pharmaceuticals to develop a modern, single use, diversion- and tamper-resistant formulation of ketamine. Moreover, we are partnering with psychiatry leaders in the US and Europe to develop a Risk Evaluation and Mitigation Strategy (REMS) program for ketamine that will include training for providers in its safe and proper use.”

NRx has advised its shareholders that it has incorporated HOPE Therapeutics, Inc. to carry forward its drug development of ketamine and will be awarding rights in HOPE to existing shareholders together with new investors.

The Keynote presentation will be simulcast; information will be available in the company’s website, as well as a question and answer session to be moderated by Bob “Sully” Sullivan of Biz Talk.